Studies how long a leukemia drug stays active in children
Observes how long calaspargase pegol stays active in children with leukemia or lymphoma.
Key facts
- Who runs it
- Mayo Clinic
- Where
- Rochester, United StatesSee the site
- Trial code
- Registry title
- Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration
- Status
- Not yet recruiting
- People taking part
- 20 people, planned
- Starts
- 1 Feb 2027
- Expected to end
- 31 Dec 2028
- Type of study
- Observational
- Treatments tested
- Non-Interventional Study
- Record updated
- 2 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and young people with acute lymphoblastic leukemia or lymphoma who are being treated by a pediatric hematology team and receive calaspargase as part of their treatment.
- Age
- Up to 21 years. People older than 21 years cannot join.
- Sex
- All sexes can join.
- Disease stage
- Acute lymphoblastic leukemia or lymphoma, treated by the pediatric hematology team.
- Earlier treatment
- Must be receiving calaspargase as part of treatment for the cancer.
Main reasons for not taking part
- Age over 21 years
- Actively enrolled on Children's Oncology Group (COG) trial AALL1732 in an inotuzumab arm
- Pregnancy
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Acute lymphoblastic leukemia/lymphoma being treated by the pediatric hematology team
- Receiving calaspargase as part of treatment for malignancy
Who cannot take part
- Age > 21 years
- Patients who are actively enrolled on Children's Oncology Group (COG) trial AALL1732 in an inotuzumab containing arm
- Pregnancy
Where in United States
- Mayo Clinic in RochesterRochester, United StatesContact: Clinical Trials Referral OfficeNot yet recruiting
About the trial
What the trial wants to find out
This study evaluates the median duration of therapeutic serum asparaginase activity (SAA) levels after administration of calaspargase pegol (Cal-PEG) and the potential association between peak SAA levels and duration of therapeutic levels with toxicity in pediatric patients with acute lymphoblastic leukemia or lymphoma.
The group in the trial
- Observational
Patients provide blood samples collected during regularly scheduled appointments and have medical records reviewed throughout the study.
Treatment: Non-Interventional Study
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration
- Plain-language title
- Studies how long a leukemia drug stays active in childrenGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 2 April 2026